SMC2-1 Antibody

What is SMC2 and why is it important in cellular biology?

SMC2 functions as a core subunit of the condensin complex, playing a critical role in DNA supercoiling – an essential process for chromosome condensation during cell division and embryonic stem cell survival. Research has established that SMC2 participates in the conversion of interphase chromatin into mitotic-like condensed chromosomes . The protein introduces positive supercoils into relaxed DNA in the presence of type I topoisomerases, a fundamental mechanism for proper chromosome organization and segregation during mitosis . Additionally, SMC2 has emerged as a transcriptional target of the WNT signaling pathway, connecting it to broader cellular regulatory networks .

What are the most commonly used detection methods for SMC2 protein expression?

Western blotting represents the primary method for SMC2 protein detection in research settings. Based on published protocols, recommended dilutions for anti-SMC2 antibodies in Western blot applications typically range from 1:1000 to 1:5000, depending on the specific antibody formulation . Immunohistochemistry on paraffin-embedded tissues (IHC-P) also provides valuable information about SMC2 localization within tissue contexts . For Western blotting, researchers have successfully used multiple commercial antibodies, including those from Abcam (ab10412, dilution 1:1000) and Upstate-Millipore (07-710, dilution 1:1000) . Actin is commonly employed as a loading control for quantitative analysis, and band intensity can be measured using software like the GeneTools Program .

What are the recommended protocols for SMC2 knockdown experiments?

For transient SMC2 knockdown, researchers have established successful protocols using siRNA. The recommended approach involves transfecting cells with 20 μM siRNA using HiPerfect Transfection Reagent (Qiagen) according to manufacturer instructions . For experiments requiring extended knockdown effects, a two-round transfection strategy has proven effective, particularly for sphere formation assays with cancer stem cells. This involves performing an initial siRNA treatment followed by a second identical treatment 72 hours later .

For stable SMC2 knockdown, lentiviral transduction represents the preferred method. This approach utilizes lentiviral particles containing shRNAs targeting SMC2, followed by puromycin selection to isolate successfully transduced cells. Multiple shRNA sequences have been validated, including MISSION shRNA clones targeting different regions of the SMC2 transcript (clone IDs NM_006444.1-3720s1c1, -1295s1c1, -1961s1c1, -3173s1c1, and -3300s1c1) . The selection of appropriate controls, including scrambled siRNA or shRNA, is essential for result interpretation.

How can researchers effectively perform chromatin immunoprecipitation (ChIP) using anti-SMC2 antibodies?

Chromatin immunoprecipitation with anti-SMC2 antibodies requires careful optimization of fixation conditions, sonication parameters, and antibody concentrations. While specific ChIP protocols for SMC2 are mentioned in the literature , key considerations include:

• Cross-linking: Standard formaldehyde fixation (1% for 10 minutes at room temperature) effectively preserves SMC2-DNA interactions

• Sonication: Optimization to achieve chromatin fragments of 200-500 bp

• Antibody selection: Using ChIP-validated anti-SMC2 antibodies

• Controls: Including IgG controls and input samples

• Quantification: qPCR analysis of precipitated DNA with primers specific to regions of interest

The resulting data can identify SMC2 binding sites across the genome, providing insights into its role in transcriptional regulation and chromosome architecture.

What quantification methods are recommended for analyzing SMC2 expression levels?

For accurate quantification of SMC2 protein levels from Western blots, researchers should employ densitometry software such as the GeneTools Program . Key methodological considerations include:

• Proper normalization to loading controls (typically actin)

• Multiple biological and technical replicates

• Statistical analysis to determine significance of expression differences

For mRNA expression analysis, real-time PCR provides reliable quantification when properly normalized to stable reference genes. Expression data can be further validated through public databases such as those used in comprehensive bioinformatic analyses of SMC2 in cancer studies .

How can antibodies against SMC2 be used for therapeutic targeting in cancer?

Innovative approaches for targeting SMC2 in cancer have emerged, including the intracellular delivery of anti-SMC2 antibodies. This strategy aims to reduce cancer malignancy by specifically targeting cancer stem cells (CSC), the tumoral subpopulation responsible for tumor recurrence and metastasis . To overcome challenges of antibody delivery across cell membranes, researchers have developed polymeric micelles (PM) based on Pluronic formulations .

The procedure involves:

• Functionalizing polymeric micelles with anti-SMC2 antibodies using EDC (polymer:EDC ratio 1:1.5)

• Incubating the formulation for 30 minutes at room temperature

• Adding the SMC2 antibody solution and incubating under stirring for 2 hours

• Optional freeze-drying for long-term storage using techniques such as VirTisBenchTop Freeze-Dryer

This approach has demonstrated effective intracellular release of antibodies targeting SMC2 in cancer cell models and shown strong cytotoxicity against CSCs, both alone and in combination with standard-of-care drugs such as 5-FU and PTX .

What are the current limitations in detecting SMC2 protein modifications?

Detection of post-translational modifications (PTMs) on SMC2 presents significant technical challenges due to:

• Limited availability of modification-specific antibodies

• Low abundance of modified forms

• Complex interactions within the condensin complex

While research has identified phosphorylation as a significant modification affecting SMC functionality in related proteins (such as SMC1A phosphorylation promoting invasion and metastasis of liver cancer cells) , specific antibodies against modified SMC2 remain limited. Researchers investigating SMC2 modifications typically employ mass spectrometry-based approaches complemented by immunoprecipitation with anti-SMC2 antibodies. This combined approach can identify modification sites and their functional significance in different cellular contexts.

How does SMC2 interact with other condensin complex components, and how can these interactions be studied?

SMC2 functions as part of the condensin complex, interacting with other key components including SMC4 and non-SMC proteins such as NCAPH . These interactions are essential for condensin complex assembly and function. Research techniques to study these interactions include:

• Co-immunoprecipitation using anti-SMC2 antibodies followed by Western blotting for interacting partners (SMC4, NCAPH)

• Proximity ligation assays to visualize protein-protein interactions in situ

• FRET/BRET approaches for dynamic interaction studies

• Mass spectrometry following immunoprecipitation to identify novel interaction partners

These approaches have revealed that SMC2 forms a heterodimer with SMC4, creating the core of the condensin complex . Additional non-SMC subunits (including NCAPH) associate with this core to form the functional condensin complex essential for chromosome condensation during mitosis.

What are common issues when using anti-SMC2 antibodies in Western blotting, and how can they be resolved?

Researchers frequently encounter several challenges when using anti-SMC2 antibodies for Western blotting:

For optimal results with anti-SMC2 antibodies in Western blotting, researchers should follow validated protocols using antibodies from reliable sources such as the mouse monoclonal antibody clone E1M (1-5 μg/ml working dilution) or rabbit polyclonal antibodies suitable for Western blotting applications .

How can researchers validate the specificity of their anti-SMC2 antibodies?

Antibody validation represents a critical step in ensuring experimental reliability. For anti-SMC2 antibodies, comprehensive validation should include:

• Positive and negative control samples (e.g., cells with known SMC2 expression levels)

• siRNA/shRNA knockdown controls to confirm band specificity

• Comparison of results from multiple antibodies targeting different epitopes

• Peptide competition assays to demonstrate binding specificity

• Western blot analysis to confirm the correct molecular weight (~135 kDa)

Researchers have successfully validated anti-SMC2 antibodies using siRNA knockdown approaches, demonstrating reduced band intensity in Western blots following SMC2 depletion . This approach provides strong evidence for antibody specificity while simultaneously confirming knockdown efficiency.

What considerations are important when selecting between monoclonal and polyclonal anti-SMC2 antibodies?

The choice between monoclonal and polyclonal anti-SMC2 antibodies should be guided by the specific research application:

For Western blot applications, both types have been successfully employed, with mouse monoclonal antibodies offering working dilutions of 1-5 μg/ml and rabbit polyclonal antibodies also providing reliable detection . The final selection should be guided by the specific experimental requirements, available validation data, and intended applications.

How does SMC2 expression correlate with clinical outcomes in cancer patients?

Comprehensive analysis of SMC2 expression in cancer contexts has revealed significant correlations with patient outcomes. In hepatocellular carcinoma, elevated SMC2 expression strongly correlates with poorer clinical outcomes across multiple survival metrics:

Additionally, SMC2 expression correlates with clinicopathological staging, suggesting its potential utility as a prognostic biomarker . These findings align with the functional role of SMC2 in promoting cancer cell proliferation and metastasis, highlighting its significance in cancer progression mechanisms.

What are the relationships between SMC2 and immune cell infiltration in tumors?

Recent immune infiltration analyses have revealed important associations between SMC2 expression and tumor immune microenvironment components. Specifically, SMC2 family expression levels show close associations with:

• B cells

• CD4+ T cells

• CD8+ T cells

• Macrophages

• Neutrophils

• Dendritic cells (DCs)

These relationships suggest potential immunomodulatory roles for SMC2 in the tumor microenvironment, which may contribute to its effects on cancer progression and treatment response. The mechanisms underlying these associations remain an active area of investigation but may involve SMC2-mediated regulation of genes involved in immune signaling and response.

How can targeting SMC2 enhance cancer treatment efficacy?

Targeting SMC2 has emerged as a promising therapeutic strategy against cancer, particularly for addressing cancer stem cells responsible for tumor recurrence and metastasis . Several approaches have demonstrated efficacy:

• siRNA/shRNA-mediated knockdown of SMC2 expression

• Intracellular delivery of anti-SMC2 antibodies using polymeric micelles

• Combination approaches with standard chemotherapeutic agents (5-FU, PTX)

Notably, intracellular delivery of anti-SMC2 antibodies has shown strong cytotoxicity against cancer stem cells both as monotherapy and in combination with standard-of-care drugs . This approach represents a novel strategy to overcome limitations of conventional treatments that fail to eliminate cancer stem cell populations. Future developments may include additional delivery systems and combination strategies to enhance clinical efficacy.

What emerging technologies might enhance SMC2 detection and functional analysis?

Emerging technologies promise to advance SMC2 research beyond current methodological limitations:

• Super-resolution microscopy for visualizing SMC2 dynamics during chromosome condensation

• CRISPR-Cas9 genome editing for generating precise SMC2 variants

• Single-cell proteomics for analyzing SMC2 expression heterogeneity

• Advanced proximity labeling techniques for identifying context-specific interaction partners

• Cryo-EM structural analysis of SMC2 within the condensin complex

These approaches will provide deeper insights into SMC2 function at molecular, cellular, and tissue levels, potentially revealing new therapeutic targeting strategies.

What are the future prospects for therapeutic targeting of SMC2 in precision medicine?

The therapeutic targeting of SMC2 shows significant promise for precision medicine applications, with several avenues for development:

• Enhanced delivery systems for anti-SMC2 antibodies beyond current polymeric micelle formulations

• Development of small molecule inhibitors specifically targeting SMC2 function

• Identification of patient subgroups most likely to benefit from SMC2 targeting

• Combination therapies targeting SMC2 alongside standard treatments

• Biomarker development to monitor treatment response

As research continues to elucidate the complex roles of SMC2 in cancer biology, these approaches may translate into clinical applications, particularly for cancer types with demonstrated SMC2 overexpression and correlation with poor outcomes .

How might single-cell analysis approaches advance our understanding of SMC2 function?

Single-cell analysis technologies offer unprecedented opportunities to understand SMC2 function with cellular resolution:

• Single-cell RNA-seq to identify cell populations with differential SMC2 expression

• Single-cell ATAC-seq to correlate SMC2 activity with chromatin accessibility patterns

• Spatial transcriptomics to map SMC2 expression within tissue contexts

• CyTOF and spectral flow cytometry for multiparameter protein analysis including SMC2

• Live-cell imaging of fluorescently-tagged SMC2 to monitor dynamics during cell cycle